Theresa Mays’s friends, colleagues establish award for pharmacists submitting abstracts to ASCO

Rathmell: To improve funding outlook, we must reverse distrust in science

With NCI funding expected to remain flat through fiscal year 2025, health professionals and leaders in oncology should use this time to amp up institutional efforts to collaborate and rebuild trust in science, NCI Director Kimryn Rathmell said.

April 12, 2024

Vol.50 No.15

By Matthew Bin Han Ong

Funding Opportunities

DOD Lung Cancer Research Program funding opportunities for FY24

The FY24 Defense Appropriations Act provides funding for the LCRP to support innovative, high-impact lung cancer research. The managing agent for the anticipated funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command.

April 12, 2024

Vol.50 No.15

NCI maintains paylines for early-stage investigators, cuts funding for other R01s and noncompeting grants in FY24

NCI is lowering paylines for R01 grants for established and new investigators to the 10th percentile, down from the 12th percentile in FY23.

April 05, 2024

Vol.50 No.14

By Matthew Bin Han Ong

In Brief

AACR recognizes 2023-2024 research grantees

The American Association for Cancer Research has named its newest class of grant recipients.

April 05, 2024

Vol.50 No.14

Conversation with The Cancer Letter

Rathmell: A tough budget is an opportunity to make sure NCI is “doing what is best for the American public”

Next week, NCI will announce its plans for surviving on an austere budget given to it by Congress as fiscal year 2024 approaches the six-month mark.

With reduced FY24 funding, NCI prepares to make cuts

Credit: National Cancer Institute, National Institutes of HealthHalfway into fiscal year 2024, NCI officials are crunching numbers, trying to find ways to live with an appropriation that, for the first time since sequestration, reduces the institute’s spending power.

March 29, 2024

Vol.50 No.13

By Matthew Bin Han Ong